Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent “as new use”

Authors: Amaral L, Molnar J
Journal: Recent Patents on Anti-Infective Drug Discovery
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Therapy+of+XDR-TB+with+thioridazine+a+drug+beyond+patent+protection+but+eligible+for+patent+%E2%80%9Cas+new+use

Mycobacterium tuberculosis that is resistant to Isoniazid (INH) and Rifampin (Rif) and hence, multi-drug resistant (MDR) has progressed to extensive drug resistant (XDR) status. XDR strains of Mycobacterium tuberculosis (XDR Mtb) are resistant, in addition to INH and Rif, to any fluoroquinolone, streptomycin and to any of the injectable anti-TB drugs kanamycin, amikacin and capreomycin.
Read More

Non-antibiotics reverse resistance of bacteria to antibiotics.

Authors: Amaral L, Kristiansen JE, Martins A, Thomsen VF, Viveiros M
Journal: In vivo
Link: http://www.ncbi.nlm.nih.gov/pubmed/20952744

BACKGROUND: Most clinical isolates that exhibit a multi-drug resistant phenotype owe that resistance to over-expressed efflux pumps. Compounds that are efflux pump inhibitors (EPIs) reduce or reverse resistance to antibiotics to which the bacterial strain is initially resistant. We have evaluated non-antibiotics to reduce resistance of commonly encountered bacterial pathogens to antibiotics. MATERIALS AND METHODS: […]
Read More

Characterization of antimicrobial resistance of Salmonella enterica food and animal isolates from Colombia: identification of a qnrB19-mediated quinolone resistance marker in two novel serovars

Ninety-three Salmonella isolates recovered from commercial foods and exotic animals in Colombia were studied. The serotypes, resistance profiles and where applicable the quinolone resistance genes were determined. Salmonella Anatum (n=14), Uganda (19), Braenderup (10) and Newport (10) were the most prevalent serovars, and resistance to tetracycline (18.3%), ampicillin (17.2%) and nalidixic acid (14%) was most […]
Read More

Ion channel blockers as antimicrobial agents, efflux inhibitors, and enhancers of macrophage killing activity against drug resistant mycobacterium tuberculosis

Authors: Amaral L, Anes E, Couto I, Machado D, Martins M, Perdigão J, Pires D, Portugal I, Viveiros M
Publication Year: 2016
Journal: PLoS One
Link: http://www.ncbi.nlm.nih.gov/pubmed/26919135

Given the ability of M. tuberculosis to survive as an intracellular pathogen and its propensity to develop resistance to the existing antituberculosis drugs, its treatment requires new approaches. Here the antimycobacterial properties of verapamil, thioridazine, chlorpromazine, flupenthixol and haloperidol were investigated against a panel of drug resistant M. tuberculosis strains, both in vitro and on human-infected macrophages.
Read More

Clinical relevance of multiple single-nucleotide polymorphisms in Pneumocystis jirovecii pneumonia: development of a multiplex PCR-single-base-extension.

Authors: Amaral L, Dastidar SG, Dutta NK, Karakousis PC, Mazumdar K
Journal: Recent Patents on Anti-Infective Drug Discovery
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=New+patentable+use+of+an+old+neuroleptic+compound+thioridazine+to+combat+tuberculosis%3A+a+gene+regulation+perspective

Use of the old antipsychotic phenothiazine thioridazine (THZ) for therapy of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) infection is now being seriously considered.
Read More

Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent “as new use”

Non-antibiotics reverse resistance of bacteria to antibiotics.

Characterization of antimicrobial resistance of Salmonella enterica food and animal isolates from Colombia: identification of a qnrB19-mediated quinolone resistance marker in two novel serovars

Ion channel blockers as antimicrobial agents, efflux inhibitors, and enhancers of macrophage killing activity against drug resistant mycobacterium tuberculosis

Clinical relevance of multiple single-nucleotide polymorphisms in Pneumocystis jirovecii pneumonia: development of a multiplex PCR-single-base-extension.

About GHTM

Contacts

Funding